LACTOLOGY FOUNDATION

A07AX04 corresponds to nifurzide, a locally acting intestinal antiinfective classified among the “other intestinal antiinfectives” and closely related in use and structure to nitrofuran derivatives such as nifuroxazide. From a toxicological‑lactological perspective, nifurzide is expected to share the profile of a poorly absorbed intestinal antibacterial with low systemic exposure, but the near‑absence of specific pharmacokinetic and lactation data means breastfeeding safety must be extrapolated cautiously and, where possible, alternative agents with better evidence should be preferred.atcddd.fhi+2

ATC classification and group definition

Nifurzide is listed under ATC code A07AX04 within group A07 “Antidiarrheals, intestinal anti‑inflammatory/anti‑infective agents” and subgroup A07A “Intestinal antiinfectives”.atccode+1
The A07AX subgroup (“Other intestinal antiinfectives”) comprises locally acting antiinfectives that cannot be placed in A07AA (antibiotics), A07AB (sulfonamides) or A07AC (imidazole derivatives).atcddd.fhi+1

Within this subgroup, the current ATC/DDD index enumerates broxyquinoline (A07AX01), acetarsol (A07AX02), nifuroxazide (A07AX03, DDD 0.6 g orally) and nifurzide (A07AX04).atcddd.fhi+1
Unlike nifuroxazide, a specific Defined Daily Dose for nifurzide is not provided in the index, reflecting limited utilisation data at the international level.atcddd.fhi

Pharmacological characteristics

Detailed mechanistic data for nifurzide are scarce in current reference sources, but its classification alongside nitrofuran intestinal antiinfectives suggests a similar mode of action: local antimicrobial activity in the intestinal lumen with limited systemic absorption.atccode+1
By analogy with related nitrofuran intestinal antiseptics, nifurzide is presumed to exert antibacterial effects through reduction of its nitro group within microbial cells, generating reactive intermediates that damage bacterial DNA, proteins and critical enzymes.synapse.patsnap+1

This mechanism would selectively target susceptible enteropathogens in the gut, reducing bacterial load and toxin production and supporting resolution of diarrhoeal illness.chemicalbook+1
As a locally acting agent, nifurzide is not intended for systemic infection, but for short‑term management of infectious diarrhoea and related gastrointestinal conditions.atcddd.fhi+1

Therapeutic indications and clinical use

Although specific product information on nifurzide is limited, inclusion in A07AX indicates its use as an oral intestinal antiinfective for infectious diarrhoea and other susceptible gastrointestinal infections.atccode+1
Agents in this subgroup are generally prescribed as short‑course therapy in acute diarrhoea, often empirically at symptom onset, to target likely bacterial or protozoal pathogens while systemic antibiotics are reserved for more severe or invasive disease.pmc.ncbi.nlm.nih+1

In practice, nifurzide may be used in some markets as an alternative or complement to nifuroxazide and similar intestinal antiseptics, particularly when local formulations or regulatory approvals favour it.atcddd.fhi+1
However, published clinical trials and comparative studies are sparse, and much of its use is guided by class experience and extrapolation from related compounds.sciencedirect+1

Dosage and administration

International ATC/DDD documentation lists nifurzide under A07AX04 without specifying a DDD, indicating that a standardised daily dose for epidemiological comparisons has not been established.atcddd.fhi
In clinical practice, dosing regimens (tablet or suspension strengths, frequency and duration) are determined by national product information and local guidelines, typically mirroring other intestinal antiinfectives with short courses over a few days.chemicalbook+1

Administration is oral, often with food to improve tolerability, and treatment is usually discontinued once diarrhoea resolves.sciencedirect+1
As with other nitrofuran‑class intestinal agents, prolonged or repeated courses are generally discouraged due to theoretical mutagenic and class‑related toxicity concerns.scribd+1

Pharmacokinetics and systemic exposure

Specific pharmacokinetic data for nifurzide in humans are not well documented in accessible sources, but its positioning as a locally acting intestinal antiinfective in A07A suggests low systemic bioavailability, similar to nifuroxazide.atcddd.fhi+1
Poor absorption from the gastrointestinal tract would lead to low maternal plasma concentrations, limiting systemic exposure and, by extension, potential transfer into breast milk.e-lactation+1

By analogy with related nitrofuran intestinal agents, most of the administered dose is expected to remain within the lumen and be excreted in faeces, with only a minor fraction absorbed and cleared via hepatic and renal pathways.ingentaconnect+1
This pharmacokinetic profile underpins the assumption of limited systemic toxicity compared with fully absorbed nitrofuran antibiotics.pubmed.ncbi.nlm.nih+1

Toxicological profile in adults

Intestinal antiseptics like nitrofuran derivatives commonly produce mild gastrointestinal adverse effects (nausea, abdominal discomfort) and occasional hypersensitivity reactions such as rash or pruritus.pmc.ncbi.nlm.nih+2
Because systemic exposure is low, serious systemic toxicity is uncommon in short‑term use, but theoretical class effects include mutagenic and carcinogenic potential with long‑term or high‑dose exposure.scribd+1

Given the paucity of nifurzide‑specific toxicity data, its safety profile is usually inferred from nitrofuran class experience, and modern regulatory practice favours limiting exposure to brief courses for acute indications.scribd+1
Patients with known nitrofuran hypersensitivity or severe hepatic or renal impairment should receive alternative treatments where possible.pubmed.ncbi.nlm.nih+1

Lactational safety and infant risk

Current lactation‑specific databases focus on nifuroxazide, noting its very low oral bioavailability and low or zero intestinal absorption, making transfer into breast milk unlikely and classifying it as very low risk and compatible with breastfeeding.e-lactation
Given nifurzide’s classification in the same ATC subgroup and presumed similar pharmacokinetic behaviour, a similar pattern of minimal maternal systemic exposure and low expected milk passage can be hypothesised, although direct data are lacking.atccode+1

General breastfeeding pharmacology emphasises that most medicines are excreted into milk at less than 10% of the maternal dose, and many antibiotics are considered compatible with breastfeeding when used at standard doses.medsafe+1
However, nitrofuran derivatives raise theoretical mutagenic concerns, and some regulatory documents for nifuroxazide recommend avoiding use in pregnancy and lactation as a precaution, despite low expected infant exposure.ema.europa+1

In the absence of nifurzide‑specific milk concentration or infant outcome data, a cautious approach is warranted: short‑term use may carry low practical risk, but preference should be given to agents with well‑documented lactational safety (e.g., nifuroxazide where positively classified, or standard systemic antibiotics with established safety records).pubmed.ncbi.nlm.nih+1

Clinical recommendations for breastfeeding women

When treating acute infectious diarrhoea in a breastfeeding woman, first‑line options should prioritise rehydration and, if needed, antibiotics with well‑established compatibility with breastfeeding (such as many penicillins, cephalosporins and macrolides), reserving intestinal antiseptics for specific scenarios.medsafe+1
If nifurzide A07AX04 is the available intestinal antiinfective, clinicians should explain the limited direct evidence, the expected low systemic and milk exposure by analogy with related agents, and the balance of benefits and theoretical risks.e-lactation+1

Short‑course therapy at standard doses is preferable, with monitoring of the infant for non‑specific gastrointestinal symptoms or hypersensitivity, though significant adverse effects are unlikely.sciencedirect+1
Special caution and a lower threshold for choosing alternative agents or enhanced monitoring are appropriate in premature or very young neonates, where intestinal permeability and susceptibility to nitrofuran class effects may be higher.pmc.ncbi.nlm.nih+1

If safer, well‑characterised alternatives are readily available and effective for the indication, they should usually be favoured over nifurzide in lactating women, given the paucity of direct lactation data.pubmed.ncbi.nlm.nih+1
Clinical documentation should reflect the rationale for drug choice, counselling provided, and plans for maternal and infant follow‑up.who+1

Educational summary for practice

A07AX04 nifurzide is a locally acting intestinal antiinfective within the “other intestinal antiinfectives” subgroup, likely functioning as a nitrofuran‑like intestinal antiseptic for acute infectious diarrhoea.atccode+1
Its presumed low systemic absorption suggests limited transfer into breast milk and a low practical risk for breastfed infants during short‑term use, but the lack of direct pharmacokinetic and lactation data supports a cautious stance and preference for better‑studied alternatives when available.e-lactation+2

In toxicological‑lactological practice, nifurzide should be approached as a secondary option in breastfeeding women, with treatment decisions grounded in individual risk–benefit assessment, availability of safer alternatives, and clear communication with the mother about evidence gaps and monitoring.medsafe+2